ONCY — Oncolytics Biotech Inc

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Oncolytics Biotech Inc

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal ("GI") tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$0.85
Market Cap$101M
Float113.7M
Shares Outstanding116.1M
P/E (Forward)45.45
Price/Sales (TTM)58.60
vs. Analyst Target+383.8% to analyst PT
Dividend RateNone
Analyst Target Price$4.11 (6 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 N/A -$16.8M -$332,652 -$16.4M
2021 N/A -$21.0M -$360,575 -$20.6M
2022 N/A -$19.1M -$301,109 -$18.7M
2023 N/A -$20.6M -$298,587 -$20.2M
2024 N/A -$31.7M N/A -$34.9M
2025 N/A -$28.8M N/A -$28.7M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Mar 2025 N/A -$6.7M
Jun 2025 N/A -$6.2M
Sep 2025 N/A -$14.4M
Dec 2025 N/A -$1.5M

Ownership & Float

Insider Ownership2.8%
Institutional Ownership2.7%
Short Float6.4%
% of All Funds Holding0.63%
Number of Funds Holding52

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$0.94Near-term / short-term trend
Weekly40-Week SMA$1.05Medium-term trend
Weekly80-Week SMA$0.90Cyclical trend (business cycle)
Weekly200-Week SMA$1.24Secular trend (multi-year)
Monthly10-Month SMA$1.02Near-term monthly trend
Monthly20-Month SMA$0.89Medium-term monthly trend
Monthly40-Month SMA$1.18Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$0.40 support 1.52x 10 months ago

Historical Earnings Reactions (94 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap -0.43% 0.00% 42.55% 9.52% -28.89%
1 Day -1.04% -0.34% 37.23% 19.05% -35.56%
1 Week -2.00% -3.04% 34.04% 48.28% -49.82%
2 Weeks -2.38% -3.28% 37.63% 51.18% -57.40%
1 Month -2.16% -3.71% 35.48% 69.34% -48.74%

Next earnings: May 13, 2026

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan-0.4%56.0%25
Feb4.1%56.0%25
Mar-0.1%36.0%25
Apr4.5%60.0%25
May-0.3%33.3%24
Jun0.6%20.8%24
Jul-3.3%37.5%24
Aug-2.6%37.5%24
Sep3.2%37.5%24
Oct8.3%50.0%24
Nov-3.5%32.0%25
Dec10.6%36.0%25

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday 0.18% 38.4% 1162
Tuesday -0.06% 38.2% 1270
Wednesday 0.14% 43.2% 1270
Thursday -0.07% 40.3% 1244
Friday 0.17% 41.2% 1241

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 2.7%

Insider Transactions — Smart Summary

Total insider ownership: 2.8%

12-Month Insider Activity Summary

Total Filings12
Net Value+$88,219.784
Net Shares Change404,282
% of Float0.4%
C-Suite Filings6
Clusters Detected1

Key Insiders

NameTitleNet ValueFilingsActivity
Seizinger Bernd R. +$83,450 1 1 buy
Kelly Jared Chief Executive Officer +$34,367.1 2 2 buy
Andrews Patricia S +$30,291.78 1 1 buy
Aromando Andrew Chief Business Officer +$25,417.52 1 1 buy
Brown Deborah Margaret +$21,240 1 1 buy
Parsons James T. +$10,300 1 1 buy
Look Kirk Chief Financial Officer +$10,104 1 1 buy
Heineman Thomas Charles Chief Medical Officer +$10,033.164 1 1 buy

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2026-02-13 – 2026-02-13 9 9 +$243,691.564 5 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-03-13 Kelly Jared Chief Executive Officer +$4,848 Transaction at $0.96, now -11.5%
2026-03-13 Parsons James T. +$10,300 Transaction at $1.03, now -17.5%
2026-02-13 Kelly Jared Chief Executive Officer +$29,519.1 Transaction at $0.84, now +1.1%
2026-02-13 Aromando Andrew Chief Business Officer +$25,417.52 Transaction at $0.86, now -1.0%
2026-02-13 Hagerman Allison VP, Product Development +$8,298 Transaction at $0.83, now +2.4%
2026-02-13 Look Kirk Chief Financial Officer +$10,104 Transaction at $0.84, now +1.0%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Oncolytics Biotech Inc (ONCY) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for ONCY on Trend Edge →